Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male Japanese and Caucasian subjects~* Age between 20 and 55 years (both inclusive) at the time of signing informed consent~* Body weight of equal to or above 54.0 kg~* Body mass index (BMI) between 20.0 and 25.0 kg/m\^2 (both inclusive)~* Glycosylated haemoglobin A1c (HbA1c) below or equal to 6.0%~* For Japanese subjects only: both parents Japanese~* For Caucasian subjects only: both parents Caucasian~Exclusion Criteria:~* Any clinically significant disease history, in the opinion of the investigator, or systemic or organ disease including: cardiological, pulmonary, gastrointestinal, hepatic, neurologic, renal, genitourinary and endocrine, dermatologic or hematologic diseases~* Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2)~* History of chronic pancreatitis or idiopathic acute pancreatitis~* Calcitonin above or equal to 50 ng/L~* History of alcohol abuse within 1 year from screening, or a positive result in the alcohol breath test, or consumption of more than 21 units of alcohol weekly: 1 unit of alcohol equals approximately 250 mL of beer or lager, or approximately120 mL (one glass) of wine or Japanese sake, or approximately 20 mL of spirits~* Smoking of more than 5 cigarettes (including nicotine substitute products) or the equivalent, per day or unwilling to refrain from smoking whenever required for the trial procedure~* Use of prescription drugs within 3 weeks or 5 times the half-life, whichever is longer, prior to Visit 2 (randomisation), non-prescription drugs within 1 week prior to Visit 2 (randomisation). The use of vitamins, minerals and nutritional supplements, and the occasional use of paracetamol (acetaminophen) or acetylsalicylic acid are permitted

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Semaglutide 0.5 mg (Type: EXPERIMENTAL): Dose-escalation trial
- Semaglutide placebo 0.5 mg (Type: PLACEBO_COMPARATOR): None
- Semaglutide 1.0 mg (Type: EXPERIMENTAL): Dose-escalation trial
- Semaglutide placebo 1.0 mg (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).